Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/LAPTM4B_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/LAPTM4B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/LAPTM4B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/LAPTM4B_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/LAPTM4B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/LAPTM4B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/LAPTM4B_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/LAPTM4B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/LAPTM4B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/LAPTM4B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19033629 | Breast | Precancer | regulation of cellular protein catabolic process | 36/1080 | 255/18723 | 6.03e-07 | 2.55e-05 | 36 |
GO:00421769 | Breast | Precancer | regulation of protein catabolic process | 47/1080 | 391/18723 | 1.50e-06 | 5.58e-05 | 47 |
GO:00313309 | Breast | Precancer | negative regulation of cellular catabolic process | 34/1080 | 262/18723 | 8.16e-06 | 2.20e-04 | 34 |
GO:00905595 | Breast | Precancer | regulation of membrane permeability | 15/1080 | 78/18723 | 3.35e-05 | 7.29e-04 | 15 |
GO:19033638 | Breast | Precancer | negative regulation of cellular protein catabolic process | 14/1080 | 75/18723 | 8.54e-05 | 1.63e-03 | 14 |
GO:00098959 | Breast | Precancer | negative regulation of catabolic process | 36/1080 | 320/18723 | 9.92e-05 | 1.83e-03 | 36 |
GO:00421779 | Breast | Precancer | negative regulation of protein catabolic process | 17/1080 | 121/18723 | 5.76e-04 | 7.28e-03 | 17 |
GO:004217614 | Breast | IDC | regulation of protein catabolic process | 63/1434 | 391/18723 | 1.32e-08 | 9.61e-07 | 63 |
GO:190336214 | Breast | IDC | regulation of cellular protein catabolic process | 46/1434 | 255/18723 | 4.00e-08 | 2.68e-06 | 46 |
GO:009055913 | Breast | IDC | regulation of membrane permeability | 17/1434 | 78/18723 | 6.88e-05 | 1.40e-03 | 17 |
GO:003133014 | Breast | IDC | negative regulation of cellular catabolic process | 37/1434 | 262/18723 | 2.20e-04 | 3.52e-03 | 37 |
GO:190336313 | Breast | IDC | negative regulation of cellular protein catabolic process | 15/1434 | 75/18723 | 4.86e-04 | 6.42e-03 | 15 |
GO:004217714 | Breast | IDC | negative regulation of protein catabolic process | 20/1434 | 121/18723 | 8.51e-04 | 9.92e-03 | 20 |
GO:000989514 | Breast | IDC | negative regulation of catabolic process | 40/1434 | 320/18723 | 1.49e-03 | 1.50e-02 | 40 |
GO:004217624 | Breast | DCIS | regulation of protein catabolic process | 62/1390 | 391/18723 | 9.98e-09 | 7.53e-07 | 62 |
GO:190336224 | Breast | DCIS | regulation of cellular protein catabolic process | 46/1390 | 255/18723 | 1.56e-08 | 1.12e-06 | 46 |
GO:009055922 | Breast | DCIS | regulation of membrane permeability | 17/1390 | 78/18723 | 4.66e-05 | 9.63e-04 | 17 |
GO:003133024 | Breast | DCIS | negative regulation of cellular catabolic process | 37/1390 | 262/18723 | 1.18e-04 | 2.07e-03 | 37 |
GO:190336323 | Breast | DCIS | negative regulation of cellular protein catabolic process | 15/1390 | 75/18723 | 3.49e-04 | 4.97e-03 | 15 |
GO:004217722 | Breast | DCIS | negative regulation of protein catabolic process | 20/1390 | 121/18723 | 5.76e-04 | 7.34e-03 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LAPTM4B | SNV | Missense_Mutation | | c.671T>A | p.Ile224Lys | p.I224K | Q86VI4 | protein_coding | deleterious(0) | probably_damaging(0.917) | TCGA-A2-A0T1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | herceptin | SD |
LAPTM4B | SNV | Missense_Mutation | | c.482N>T | p.Ala161Val | p.A161V | Q86VI4 | protein_coding | tolerated(0.06) | probably_damaging(0.975) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
LAPTM4B | SNV | Missense_Mutation | novel | c.563N>A | p.Arg188His | p.R188H | Q86VI4 | protein_coding | tolerated(0.77) | benign(0.007) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LAPTM4B | SNV | Missense_Mutation | | c.511N>G | p.Leu171Val | p.L171V | Q86VI4 | protein_coding | tolerated(0.31) | benign(0.038) | TCGA-BM-6198-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | SD |
LAPTM4B | SNV | Missense_Mutation | rs147058372 | c.815N>A | p.Arg272Gln | p.R272Q | Q86VI4 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LAPTM4B | SNV | Missense_Mutation | novel | c.585C>A | p.Phe195Leu | p.F195L | Q86VI4 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LAPTM4B | SNV | Missense_Mutation | novel | c.794N>A | p.Ser265Asn | p.S265N | Q86VI4 | protein_coding | tolerated(0.51) | possibly_damaging(0.828) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
LAPTM4B | SNV | Missense_Mutation | | c.811N>C | p.Tyr271His | p.Y271H | Q86VI4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
LAPTM4B | SNV | Missense_Mutation | rs201585055 | c.674N>A | p.Arg225Gln | p.R225Q | Q86VI4 | protein_coding | tolerated(0.34) | benign(0.277) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LAPTM4B | SNV | Missense_Mutation | novel | c.461N>G | p.Asp154Gly | p.D154G | Q86VI4 | protein_coding | deleterious(0) | possibly_damaging(0.676) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |